Progenics, Salix tumble on US FDA snub for expanded Relistor marketing
13:20 EDT 30 Jul 2012 | SCRIP
Shares of Tarrytown, New York-based Progenics lost half their value on 30 July on word the US FDA refused to let the company and its partner Salix Pharmaceuticals market Relistor (methylnaltrexone bromide) injection as a subcutaneous treatment fo..
Original Article: Progenics, Salix tumble on US FDA snub for expanded Relistor marketing
More From BioPortfolio on "Progenics, Salix tumble on US FDA snub for expanded Relistor marketing"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
